A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

Sultana, Arifa; Shahriar, Saimon; Tahsin, Rafat; Mim, Sabiha Rahman; Fatema, Kazi Rubiya; Saha, Ananya; Yesmin, Fahmida; Bahar, Nasiba Binte; Samodder, Mithun; Mamun, Ariful Haque; Rahman, Aknur; Ferdousy, Sonia; Akter, Tahmina; Aktar, Fahima; Kuddus, Mohammed; Rahman, Mustafizur; Sarker, Md. Moklesur Rahman; Büyüker, Sultan Mehtap; Chowdhury, Jakir Ahmed; Chowdhury, Abu Asad; Kabir, Shaila; Hossain, Akter; Amran, Shah

doi:10.3390/vaccines9101090

Cited by 21 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, less than half of the participants (47.6%) experienced at least one side effect while remaining study participants (52.38%) experienced more than one side effect. Our study results confirmed that most of the side effects were mild in nature as have been observed in other studies conducted elsewhere ( Shrestha et al, 2021 ; Konu et al, 2021 ; Watcharananan et al, 2022; Sultana et al, 2021 ) including in some African settings ( Konu et al, 2021 ). Our findings of odds of women experiencing more acute and severe AEFI from the Covishield vaccine (ChAdOx1 nCoV-19 vaccine) than males has also been observed in Thailand (Watcharananan et al, 2022), Nepal ( Shrestha et al, 2021 ) and in Bangladesh ( Sultana et al, 2021 ).…”

Section: Discussionsupporting

confidence: 92%

“…Our study results confirmed that most of the side effects were mild in nature as have been observed in other studies conducted elsewhere ( Shrestha et al, 2021 ; Konu et al, 2021 ; Watcharananan et al, 2022; Sultana et al, 2021 ) including in some African settings ( Konu et al, 2021 ). Our findings of odds of women experiencing more acute and severe AEFI from the Covishield vaccine (ChAdOx1 nCoV-19 vaccine) than males has also been observed in Thailand (Watcharananan et al, 2022), Nepal ( Shrestha et al, 2021 ) and in Bangladesh ( Sultana et al, 2021 ). This finding is also consistent with other data published on the COVID-19 vaccine ( Gee et al, 2021 ; Blumenthal et al, 2021 ).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future

Hamayoun¹,

Abdulrazak²,

Farid³

et al. 2022

IJID Regions

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future

Hamayoun¹,

Abdulrazak²,

Farid³

et al. 2022

IJID Regions

View full text Add to dashboard Cite

“…In the present study, the overall incidence of adverse events following vaccination was found to be 29.8% which is in contrast to a study conducted in Bangladesh [14]. The incidence of adverse events following vaccination was found to be 2.47% immediately following vaccination, 6.78% experienced adverse reactions in the observation room, and 25.3% experienced reactions after the observation period.…”

Section: Incidence and Side-effects After Vaccinationcontrasting

confidence: 99%

Post-vaccination side effects following the second dose of COVID-19 vaccine among health care workers

Jain

Selvaraju

Ganesan

et al. 2022

IJPHS

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) vaccines were launched after granting them ‘emergency use authorization’ approval. Beyond the clinical trial, there was very limited data on the side effects following vaccination This is a longitudinal study among health care workers (HCWs) in a tertiary care hospital. Information was also collected using a pre-tested semi-structured questionnaire which included their demographic details, first dose and second dose. Post-vaccination follow-up was done at the centre which was then followed up by telephonic monitoring after 48 hours. In the present study 1,034 (65.6%) health care workers (HCWs) did not report any serious reactions/symptoms. Pain and tenderness were the most commonly reported side-effects in more than half. The severity of the symptoms following the second dose of vaccine was compared with the first dose and it was found that the majority 653 (41.4%) had reported no symptoms/reactions following both doses of vaccine. Every vaccine will have some side effects but it is important to understand that in the ongoing pandemic, vaccines are our “best shot” to fight against this virus.

show abstract

“…Both were within the range of self-report surveys. The former has shown prevalence ranging from 51 to 96% ( 21 , 27 , 35 , 38 , 39 ) and the second one, prevalence ranging from 71 to 82% ( 40 , 41 ).…”

Section: Discussionmentioning

confidence: 99%

Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

Camacho-Moll

Salinas-Martı́nez

Cisneros

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared the extension and severity of self-reported side effects of seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen)] in the Mexican population. We also evaluated the association of type of vaccine, sex, age, comorbidity, and history of allergies to the extent and severity of side effects. This was a cross-sectional study carried out online between August 12 and September 3, 2021 in Mexico. The first inclusion criterion was to receive a COVID-19 vaccine and the second, being at least 18 years old. The survey link was distributed via multiple social media platforms. We questioned about the type of vaccine and symptoms based on short-term side effects reported in the literature. Side effect extension was classified as local, systemic, or both. We asked about the need to take medicine, stop activities/miss work, or seek medical attention. Then, a severity index was constructed based on responses. Descriptive and stepwise multivariate logistic ordinal regression analyses were used to calculate odds ratio (OR) and 95% CI for each outcome adjusted by potential confounders. The mean age was 38.9 ± 11.0 years (n = 4,024). Prevalence of at least one side effect varied between vaccines and by a number of doses. At dose 1, ChAdOx1 was the vaccine with the highest rate of at least one side effect (85%) followed by Gam-COVID-Vac (80%). Both were associated to greater extension (adjusted OR 2.53, 95% CI 2.16, 2.96 and adjusted OR 2.41, 95% CI 1.76, 3.29, respectively) and severity of side effects (adjusted OR 4.32, 95% CI 3.73, 5.00 and adjusted OR 3.00, 95% CI 2.28, 3.94, respectively). Young age (<50 years), female sex, comorbidity, and history of allergies were associated with greater extension and severity, independent of the type of vaccine and potential confounders. At dose 2, mRNA-1273 was the vaccine with the highest rate of side effects (88%) and the only vaccine associated to greater extension (adjusted OR 2.88, 95% CI 1.59, 5.21) and severity of symptoms (adjusted OR 3.14, 95% CI 1.82, 5.43). Continuous studies are necessary to acknowledge more post-vaccine symptoms in different populations.

show abstract

A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh

Cited by 21 publications

References 31 publications

Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future

Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future

Post-vaccination side effects following the second dose of COVID-19 vaccine among health care workers

Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

Contact Info

Product

Resources

About